SIRO Clinpharm, a CRO with a presence in Asia, Europe and U.S., has completed a trial project for Peregrine Pharmaceuticals, a clinical-stage biopharma developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections.   The Phase II trial in India involved recurrent glioblastoma multiforme (GBM) patients treated with Cotara, an investigational radiopharmaceutical product. SIRO was assigned to identify and manage the Indian arm of the trial across multiple sites, a...